Bispecific antibodies against CD3ϵ and BCMA

US10253104B2 · kind B2 · utility

Assignee

• ENGMAB AG · CH

Inventors

• Minh Diem Vu · Wollerau, CH
• Klaus Strein · Hemsbach, DE
• Oliver Ast · Bassersdorf, CH
• Marina BACAC · Schlieren, CH
• Lydia Jasmin Hanisch · Schlieren, CH
• Tanja Fauti · Zürich, CH
• Anne Freimoser-Grundschober · Bellinzona, CH
• Ralf Hosse · Baar, CH
• Christian Klein · Iffeldorf, DE
• Ekkehard Moessner · Kreuzlingen, CH
• Samuel Moser · Rotkreuz, CH
• Ramona MURR · Zürich, CH
• Pablo Umana · Wollerau, CH
• Sabine Jung-Imhof · Planegg, DE
• Stefan Klostermann · Schwanau, DE
• Michael Molhoj · Munich, DE
• Joerg Thomas Regula · Munich, DE
• Wolfgang Schaefer · Sankt Augustin, DE

Key dates

• Filing date: Aug 3, 2015
• Grant date: Apr 9, 2019
• Expiry date: Aug 3, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3ε, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.